Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.
Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M. Facchinetti F, et al. Among authors: squadrilli a. Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175. Immunotherapy. 2018. PMID: 29882691
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G, Minari R, Zecca A, Cavazzoni A, Ferri V, Mori C, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Missale G, Petronini PG, Quaini F, Tiseo M. Mazzaschi G, et al. Among authors: squadrilli a. Lung Cancer. 2020 Oct;148:1-11. doi: 10.1016/j.lungcan.2020.07.028. Epub 2020 Aug 2. Lung Cancer. 2020. PMID: 32768804
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
Bozzetti C, Squadrilli A, Nizzoli R, Lagrasta C, Gasparro D, Majori M, Filippo M, Becchi G, Azzoni C, Campanini N, Pedrazzi G, Zavani A, Silini EM, Tiseo M, Gnetti L. Bozzetti C, et al. Among authors: squadrilli a. Immunotherapy. 2020 Feb;12(3):183-193. doi: 10.2217/imt-2019-0138. Epub 2020 Feb 18. Immunotherapy. 2020. PMID: 32066299
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R, Bonatti F, Mazzaschi G, Dodi A, Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Quaini F, Ardizzoni A, Tiseo M. Minari R, et al. Among authors: squadrilli a. Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18. Tumori. 2022. PMID: 34002648
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, Mazzoni F, Maddau C, Naldi N, Sammarelli G, Frati C, Pinto C, Ardizzoni A. Bozzetti C, et al. Among authors: squadrilli a. Diagn Cytopathol. 2015 Nov;43(11):941-6. doi: 10.1002/dc.23318. Epub 2015 Jul 7. Diagn Cytopathol. 2015. PMID: 26152804
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M. Bordi P, et al. Among authors: squadrilli a. Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19. Lung Cancer. 2019. PMID: 31027702 Clinical Trial.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Dall'Olio FG, Abbati F, Facchinetti F, Massucci M, Melotti B, Squadrilli A, Buti S, Formica F, Tiseo M, Ardizzoni A. Dall'Olio FG, et al. Among authors: squadrilli a. Ther Adv Med Oncol. 2020 Oct 31;12:1758835920952994. doi: 10.1177/1758835920952994. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33193825 Free PMC article.
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.
Bozzetti C, Quaini F, Squadrilli A, Tiseo M, Frati C, Lagrasta C, Azzoni C, Bottarelli L, Galetti M, Alama A, Belletti S, Gatti R, Passaro A, Gradilone A, Cavazzoni A, Alfieri R, Petronini PG, Bonelli M, Falco A, Carubbi C, Pedrazzi G, Nizzoli R, Naldi N, Pinto C, Ardizzoni A. Bozzetti C, et al. Among authors: squadrilli a. PLoS One. 2015 Nov 16;10(11):e0142891. doi: 10.1371/journal.pone.0142891. eCollection 2015. PLoS One. 2015. PMID: 26571236 Free PMC article.
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report.
Minari R, Gnetti L, Lagrasta CA, Squadrilli A, Bordi P, Azzoni C, Bottarelli L, Cosenza A, Ferri L, Caruso G, Silini EM, Tiseo M. Minari R, et al. Among authors: squadrilli a. Transl Lung Cancer Res. 2020 Jun;9(3):787-792. doi: 10.21037/tlcr.2020.04.03. Transl Lung Cancer Res. 2020. PMID: 32676339 Free PMC article.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Negrini M, Tiseo M, Ferracin M, Ardizzoni A. Cinausero M, et al. Among authors: squadrilli a. Ther Adv Med Oncol. 2019 Nov 14;11:1758835919885540. doi: 10.1177/1758835919885540. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31798692 Free PMC article.
17 results